221 related articles for article (PubMed ID: 19883882)
61. Reassessments of ESAs for cancer treatment in the US and Europe.
Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
[TBL] [Abstract][Full Text] [Related]
62. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
63. Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).
Veys N; Van Biesen W; Lameire N
Acta Clin Belg; 2007; 62(6):396-407. PubMed ID: 18351184
[No Abstract] [Full Text] [Related]
64. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
65. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
66. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
67. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
[TBL] [Abstract][Full Text] [Related]
68. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
69. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
70. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
71. Erythropoiesis stimulating agents and anaemia of end-stage renal disease.
Schmid H; Schiffl H
Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):164-72. PubMed ID: 20443766
[TBL] [Abstract][Full Text] [Related]
72. Erythropoiesis-stimulating agents: dose and mortality risk.
Bellinghieri G; Condemi CG; Saitta S; Trifirò G; Gangemi S; Savica V; Buemi M; Santoro D
J Ren Nutr; 2015 Mar; 25(2):164-8. PubMed ID: 25529282
[TBL] [Abstract][Full Text] [Related]
73. Tips for erythropoiesis-stimulating agent treatment of renal anemia.
Tomosugi N; Koshino Y
Clin Exp Nephrol; 2020 Jan; 24(1):105-106. PubMed ID: 31617026
[No Abstract] [Full Text] [Related]
74. The new FDA labeling for ESA--implications for patients and providers.
Manns BJ; Tonelli M
Clin J Am Soc Nephrol; 2012 Feb; 7(2):348-53. PubMed ID: 22266575
[TBL] [Abstract][Full Text] [Related]
75. Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.
Kuragano T; Nakanishi T
Contrib Nephrol; 2018; 196():52-57. PubMed ID: 30041204
[TBL] [Abstract][Full Text] [Related]
76. Anemia therapy in ESRD: time to move on.
Folkert VW; Meyer TW; Hostetter TH
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1163-4. PubMed ID: 20538832
[No Abstract] [Full Text] [Related]
77. Erythropoiesis-stimulating agents (ESAs), from chemotherapy-induced anemia to any cancer-related anemia?
Venturino A; Colloca G
Ann Oncol; 2010 Apr; 21(4):905-906. PubMed ID: 20032124
[No Abstract] [Full Text] [Related]
78. Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure.
Lindquist DE; Cruz JL; Brown JN
J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):59-65. PubMed ID: 24996902
[TBL] [Abstract][Full Text] [Related]
79. Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents.
Moist LM; Foley RN; Barrett BJ; Madore F; White CT; Klarenbach SW; Culleton BF; Tonelli M; Manns BJ;
Kidney Int Suppl; 2008 Aug; (110):S12-8. PubMed ID: 18668116
[No Abstract] [Full Text] [Related]
80. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.
Wish JB; Nassar GM; Schulman K; del Aguila M; Provenzano R
Clin Nephrol; 2008 Apr; 69(4):251-9. PubMed ID: 18397699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
